Article on RhoVac’s Phase I/II study to be published in November
Lund, October 26, 2020. RhoVac AB (“RhoVac”) announces today that the publication of the article on RhoVac’s Phase I/II study is set to be published in November.As previously disclosed, the article elaborating on the results of RhoVac’s Phase I/II study in prostate cancer including the 12-month follow-up period, has been accepted for publication in the Journal for ImmunoTherapy of Cancer (JITC). The publication now indicates that the release of the article will take place in November, a few weeks later than previously suggested. The article will feature an elaboration on the mode of action